Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis

IMPORTANCE: Rituximab and other B-cell–depleting therapies blunt humoral responses to SARS-CoV-2 vaccines, particularly when the vaccine is administered within 6 months of an infusion. Whether this translates into an increased risk of hospitalization or death from COVID-19 is unclear. OBJECTIVES: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Jessica B., Gonzales, Edlin G., Li, Bonnie H., Langer-Gould, Annette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857265/
https://www.ncbi.nlm.nih.gov/pubmed/36576740
http://dx.doi.org/10.1001/jamanetworkopen.2022.48664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857265/
https://www.ncbi.nlm.nih.gov/pubmed/36576740
http://dx.doi.org/10.1001/jamanetworkopen.2022.48664

Ejemplares similares